VUG - Vanguard Growth ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
148.65
-0.22 (-0.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close148.87
Open148.66
Bid0.00 x 1000
Ask0.00 x 900
Day's Range148.40 - 149.06
52 Week Range125.79 - 152.38
Volume472,360
Avg. Volume770,559
Net Assets75.68B
NAV142.27
PE Ratio (TTM)73.23
Yield1.12%
YTD Return1.41%
Beta (3y)1.06
Expense Ratio (net)0.05%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Vanguard, genocide, and the $18 million campaign to get you to vote
    Yahoo Finance Video7 months ago

    Vanguard, genocide, and the $18 million campaign to get you to vote

    An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.

  • Total Returns and Sector Exposure for Growth Indexes
    Market Realist5 days ago

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...

  • 5 Ultra-Cheap Growth ETFs for a Large-Cap Play This Spring
    InvestorPlace2 months ago

    5 Ultra-Cheap Growth ETFs for a Large-Cap Play This Spring

    Volatility and uncertainty have been playing foul in the U.S. stock market over the past couple of months. While the list of worries include higher rates, Washington turmoil, and tech selloff, the latest reason for the sluggish trading remains fears over a trade war between the United States and China.Source: Shutterstock

  • 7 of the Best Growth ETFs
    InvestorPlace3 months ago

    7 of the Best Growth ETFs

    Although stocks have recently given back some of their short-term gains, the market big picture remains within the frame of momentum, which makes for a good environment to look to growth exchange-traded funds (ETFs).

  • How Biogen’s Biosimilars and Interferons Performed in 4Q17
    Market Realist4 months ago

    How Biogen’s Biosimilars and Interferons Performed in 4Q17

    Biogen: How It Performed in 4Q17

  • What Yellen's Final Meeting Means for These ETFs
    Zacks4 months ago

    What Yellen's Final Meeting Means for These ETFs

    Yellen's final meeting puts these ETFs in focus.

  • Investopedia4 months ago

    Another Record for Smart Beta Assets

    Smart beta ETFs tallied another record year of asset gathering in 2017.

  • Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results
    Market Realist4 months ago

    Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results

    Thermo Fisher Scientific: Strong Momentum for 4Q17?Analyst recommendations

  • 3 Large-Cap Growth ETFs for Your Portfolio
    Zacks4 months ago

    3 Large-Cap Growth ETFs for Your Portfolio

    Large-cap growth ETFs are attracting attention, owing to a strong pickup in global economic growth.

  • AbbVie’s Rova-T: Solid Growth Driver for the Future?
    Market Realist4 months ago

    AbbVie’s Rova-T: Solid Growth Driver for the Future?

    Exploring AbbVie’s Oncology, Virology, and Neurology Portfolios

  • What’s Driving Baxter International’s Cash Flow Growth
    Market Realist4 months ago

    What’s Driving Baxter International’s Cash Flow Growth

    Baxter Reaches 52-Week High: What's behind the Stock Rally?

  • AbbVie’s Position in the Growing Oncology Market in 2018
    Market Realist4 months ago

    AbbVie’s Position in the Growing Oncology Market in 2018

    AbbVie (ABBV) is focused on advancing its already strong position in the hematologic oncology segment in 2018. The overall hematologic malignancy and solid tumor market in the US is currently worth $87 billion and is expected to reach a market value of $169 billion by 2025. According to estimates from American Cancer Society, SEER, Kantar Health, IMS Institute Healthcare Informatics, Global Oncology Trend Report, and Evaluate Pharma, the total number of cancer patients worldwide is expected to reach 19 million by 2025.

  • 7 Best Cheap Index Funds and ETFs to Buy
    InvestorPlace5 months ago

    7 Best Cheap Index Funds and ETFs to Buy

    Fund fees, be they index fund or exchange-traded fund (ETF) fees, continue dropping and that is great news for investors.

  • Align Technology’s Customer Acquisition Strategy Driving Market Growth
    Market Realist5 months ago

    Align Technology’s Customer Acquisition Strategy Driving Market Growth

    Align Technology (ALGN) increased its expenditure toward consumer marketing by 60% in 2017. The increase in Invisalign treatment adoption rates across the teen and adult segments are driven by the company’s consumer marketing and sales initiatives. Peers Dentsply Sirona (XRAY), Zimmer Biomet Holdings (ZBH), and Henry Schein (HSIC) expect to post SG&A (selling, general, and administrative) expenses of 37.0%, 38.0%, and 20.0%, respectively, in their recent fiscal years.

  • Market Realist6 months ago

    Can Smart Beta Go Wrong?

    The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.

  • 3 Top Vanguard ETFs in 2017
    Motley Fool6 months ago

    3 Top Vanguard ETFs in 2017

    Find out which exchange-traded funds from this fund giant have delivered strong returns.

  • Investopedia7 months ago

    Getting Better Acquainted With Smart Beta ETFs

    The world of smart beta ETFs is expansive and getting bigger by the day.

  • Market Realist7 months ago

    Allergan Stock: Performance in 3Q17

    Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.

  • Vanguard, genocide, and the $18 million campaign to get you to vote
    Yahoo Finance7 months ago

    Vanguard, genocide, and the $18 million campaign to get you to vote

    Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?

  • 3 Top Ranked Large-Cap Growth ETFs for Your Portfolio
    Zacks7 months ago

    3 Top Ranked Large-Cap Growth ETFs for Your Portfolio

    Large-cap growth ETFs are garnering a lot of attention, owing to global economic growth.

  • Benzinga8 months ago

    A Solid Start For This New ETF

    This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...

  • Market Realist8 months ago

    Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver?

    According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.

  • Market Realist8 months ago

    BD Stock Fell 2.7% on September 13: Should Investors Worry?

    Becton, Dickinson and Company (BDX) closed at $196.62 on September 13, 2017.

  • Benzinga8 months ago

    Going With Growth ETFs

    This year, the growth factor resumed its outperformance of the value factor, benefiting a host of exchange traded funds along the way. Investors can easily access growth stocks via ETFs, whether be by ...

  • ETF Trends8 months ago

    10 Super-Cheap Vanguard ETFs for Investors

    ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...